While considered as a late event in sporadic CRC [9,10], TP53 mutations occur very early in patients with IBD-associated CRC, before neoplastic deletion becomes detectable [11,12], and have been associated with NOS2 activity [13]. Here, TP53 is linked to colorectal carcinoma.